Question special

Adherence to GDMT for heart failure is suboptimal. GDMT for HFrEF includes an ACEi/ARB/ARNI, beta-blocker/ivabradine, and MRA. The “polypill” is a fixed-dose combination of medications for the prevention of CVD. The SCCS Polypill Pilot trial showed adherence to a polypill regimen is high (86% at 12 months). Additionally, the polypill led to greater reductions in SBP and LDL levels compared to the usual-care group in persons with low socioeconomic status.

Does the polypill have a role in improving adherence rates to GDMT in patients with HFrEF? What other strategies are under development for improving adherence rates?